Intrinsic value of Mallinckrodt - MNK

Previous Close

$21.66

  Intrinsic Value

$87.47

stock screener

  Rating & Target

str. buy

+304%

Previous close

$21.66

 
Intrinsic value

$87.47

 
Up/down potential

+304%

 
Rating

str. buy

We calculate the intrinsic value of MNK stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  3,286
  3,362
  3,448
  3,545
  3,653
  3,771
  3,899
  4,038
  4,188
  4,349
  4,521
  4,704
  4,900
  5,107
  5,327
  5,561
  5,808
  6,069
  6,346
  6,637
  6,945
  7,269
  7,611
  7,972
  8,351
  8,751
  9,171
  9,614
  10,079
  10,569
Variable operating expenses, $m
  2,661
  2,695
  2,734
  2,778
  2,826
  2,879
  2,936
  2,999
  3,066
  3,138
  2,030
  2,112
  2,200
  2,293
  2,392
  2,497
  2,608
  2,725
  2,849
  2,980
  3,118
  3,264
  3,417
  3,579
  3,749
  3,929
  4,118
  4,316
  4,525
  4,745
Fixed operating expenses, $m
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
Total operating expenses, $m
  2,660
  2,694
  2,733
  2,777
  2,825
  2,878
  2,935
  2,998
  3,065
  3,137
  2,029
  2,111
  2,199
  2,292
  2,391
  2,496
  2,607
  2,724
  2,847
  2,978
  3,116
  3,262
  3,415
  3,577
  3,747
  3,927
  4,116
  4,314
  4,523
  4,743
Operating income, $m
  626
  668
  715
  769
  828
  893
  964
  1,041
  1,123
  1,212
  2,492
  2,593
  2,701
  2,816
  2,937
  3,066
  3,202
  3,346
  3,498
  3,659
  3,828
  4,007
  4,196
  4,394
  4,603
  4,824
  5,055
  5,299
  5,556
  5,826
EBITDA, $m
  3,167
  3,239
  3,323
  3,416
  3,520
  3,633
  3,757
  3,891
  4,035
  4,190
  4,356
  4,533
  4,721
  4,921
  5,133
  5,358
  5,596
  5,848
  6,114
  6,395
  6,691
  7,004
  7,333
  7,680
  8,046
  8,431
  8,836
  9,262
  9,711
  10,182
Interest expense (income), $m
  0
  372
  382
  394
  407
  421
  438
  456
  475
  496
  519
  544
  570
  598
  627
  659
  692
  728
  765
  805
  847
  891
  938
  987
  1,039
  1,094
  1,152
  1,213
  1,276
  1,344
  1,414
Earnings before tax, $m
  254
  286
  322
  362
  407
  455
  508
  565
  627
  693
  1,949
  2,024
  2,104
  2,188
  2,278
  2,373
  2,474
  2,581
  2,693
  2,812
  2,937
  3,069
  3,208
  3,355
  3,509
  3,672
  3,843
  4,023
  4,212
  4,411
Tax expense, $m
  69
  77
  87
  98
  110
  123
  137
  153
  169
  187
  526
  546
  568
  591
  615
  641
  668
  697
  727
  759
  793
  829
  866
  906
  948
  991
  1,038
  1,086
  1,137
  1,191
Net income, $m
  185
  209
  235
  264
  297
  332
  371
  413
  458
  506
  1,423
  1,477
  1,536
  1,597
  1,663
  1,733
  1,806
  1,884
  1,966
  2,053
  2,144
  2,240
  2,342
  2,449
  2,562
  2,680
  2,805
  2,937
  3,075
  3,220

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  15,215
  15,565
  15,965
  16,414
  16,912
  17,458
  18,052
  18,696
  19,389
  20,133
  20,929
  21,779
  22,683
  23,644
  24,664
  25,745
  26,889
  28,099
  29,378
  30,728
  32,152
  33,654
  35,237
  36,905
  38,662
  40,512
  42,459
  44,508
  46,664
  48,931
Adjusted assets (=assets-cash), $m
  15,215
  15,565
  15,965
  16,414
  16,912
  17,458
  18,052
  18,696
  19,389
  20,133
  20,929
  21,779
  22,683
  23,644
  24,664
  25,745
  26,889
  28,099
  29,378
  30,728
  32,152
  33,654
  35,237
  36,905
  38,662
  40,512
  42,459
  44,508
  46,664
  48,931
Revenue / Adjusted assets
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
  0.216
Average production assets, $m
  13,547
  13,858
  14,214
  14,614
  15,057
  15,543
  16,073
  16,646
  17,263
  17,926
  18,634
  19,391
  20,196
  21,052
  21,960
  22,922
  23,941
  25,018
  26,156
  27,358
  28,626
  29,964
  31,373
  32,859
  34,423
  36,070
  37,804
  39,628
  41,547
  43,566
Working capital, $m
  230
  235
  241
  248
  256
  264
  273
  283
  293
  304
  316
  329
  343
  358
  373
  389
  407
  425
  444
  465
  486
  509
  533
  558
  585
  613
  642
  673
  706
  740
Total debt, $m
  6,587
  6,785
  7,012
  7,266
  7,548
  7,857
  8,193
  8,558
  8,950
  9,371
  9,822
  10,302
  10,814
  11,358
  11,936
  12,547
  13,195
  13,880
  14,603
  15,367
  16,174
  17,024
  17,920
  18,864
  19,859
  20,906
  22,008
  23,167
  24,387
  25,671
Total liabilities, $m
  8,612
  8,810
  9,036
  9,290
  9,572
  9,881
  10,218
  10,582
  10,974
  11,395
  11,846
  12,327
  12,839
  13,383
  13,960
  14,572
  15,219
  15,904
  16,628
  17,392
  18,198
  19,048
  19,944
  20,888
  21,883
  22,930
  24,032
  25,192
  26,412
  27,695
Total equity, $m
  6,603
  6,755
  6,929
  7,124
  7,340
  7,577
  7,835
  8,114
  8,415
  8,738
  9,083
  9,452
  9,844
  10,262
  10,704
  11,173
  11,670
  12,195
  12,750
  13,336
  13,954
  14,606
  15,293
  16,017
  16,779
  17,582
  18,427
  19,317
  20,252
  21,236
Total liabilities and equity, $m
  15,215
  15,565
  15,965
  16,414
  16,912
  17,458
  18,053
  18,696
  19,389
  20,133
  20,929
  21,779
  22,683
  23,645
  24,664
  25,745
  26,889
  28,099
  29,378
  30,728
  32,152
  33,654
  35,237
  36,905
  38,662
  40,512
  42,459
  44,509
  46,664
  48,931
Debt-to-equity ratio
  1.000
  1.000
  1.010
  1.020
  1.030
  1.040
  1.050
  1.050
  1.060
  1.070
  1.080
  1.090
  1.100
  1.110
  1.120
  1.120
  1.130
  1.140
  1.150
  1.150
  1.160
  1.170
  1.170
  1.180
  1.180
  1.190
  1.190
  1.200
  1.200
  1.210
Adjusted equity ratio
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434
  0.434

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  185
  209
  235
  264
  297
  332
  371
  413
  458
  506
  1,423
  1,477
  1,536
  1,597
  1,663
  1,733
  1,806
  1,884
  1,966
  2,053
  2,144
  2,240
  2,342
  2,449
  2,562
  2,680
  2,805
  2,937
  3,075
  3,220
Depreciation, amort., depletion, $m
  2,540
  2,572
  2,607
  2,647
  2,692
  2,740
  2,793
  2,850
  2,912
  2,978
  1,863
  1,939
  2,020
  2,105
  2,196
  2,292
  2,394
  2,502
  2,616
  2,736
  2,863
  2,996
  3,137
  3,286
  3,442
  3,607
  3,780
  3,963
  4,155
  4,357
Funds from operations, $m
  2,726
  2,780
  2,842
  2,912
  2,988
  3,073
  3,164
  3,263
  3,370
  3,484
  3,286
  3,416
  3,555
  3,703
  3,859
  4,025
  4,200
  4,386
  4,582
  4,788
  5,007
  5,237
  5,479
  5,735
  6,004
  6,287
  6,586
  6,899
  7,230
  7,577
Change in working capital, $m
  5
  5
  6
  7
  8
  8
  9
  10
  10
  11
  12
  13
  14
  15
  15
  16
  17
  18
  19
  20
  22
  23
  24
  25
  27
  28
  29
  31
  33
  34
Cash from operations, $m
  2,721
  2,775
  2,836
  2,905
  2,981
  3,064
  3,155
  3,253
  3,359
  3,473
  3,274
  3,404
  3,542
  3,688
  3,844
  4,008
  4,183
  4,367
  4,562
  4,768
  4,985
  5,214
  5,455
  5,710
  5,978
  6,259
  6,556
  6,869
  7,197
  7,543
Maintenance CAPEX, $m
  -1,328
  -1,355
  -1,386
  -1,421
  -1,461
  -1,506
  -1,554
  -1,607
  -1,665
  -1,726
  -1,793
  -1,863
  -1,939
  -2,020
  -2,105
  -2,196
  -2,292
  -2,394
  -2,502
  -2,616
  -2,736
  -2,863
  -2,996
  -3,137
  -3,286
  -3,442
  -3,607
  -3,780
  -3,963
  -4,155
New CAPEX, $m
  -269
  -312
  -356
  -400
  -443
  -486
  -529
  -573
  -617
  -663
  -709
  -756
  -805
  -856
  -908
  -962
  -1,019
  -1,077
  -1,138
  -1,202
  -1,268
  -1,337
  -1,410
  -1,485
  -1,564
  -1,647
  -1,734
  -1,824
  -1,919
  -2,019
Cash from investing activities, $m
  -1,597
  -1,667
  -1,742
  -1,821
  -1,904
  -1,992
  -2,083
  -2,180
  -2,282
  -2,389
  -2,502
  -2,619
  -2,744
  -2,876
  -3,013
  -3,158
  -3,311
  -3,471
  -3,640
  -3,818
  -4,004
  -4,200
  -4,406
  -4,622
  -4,850
  -5,089
  -5,341
  -5,604
  -5,882
  -6,174
Free cash flow, $m
  1,125
  1,109
  1,094
  1,084
  1,076
  1,072
  1,071
  1,073
  1,077
  1,084
  773
  784
  797
  813
  830
  850
  872
  896
  922
  951
  981
  1,014
  1,049
  1,087
  1,127
  1,170
  1,216
  1,264
  1,315
  1,369
Issuance/(repayment) of debt, $m
  166
  198
  226
  254
  282
  309
  337
  364
  392
  421
  451
  481
  512
  544
  577
  612
  648
  685
  724
  764
  806
  850
  896
  944
  994
  1,047
  1,102
  1,160
  1,220
  1,283
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  166
  198
  226
  254
  282
  309
  337
  364
  392
  421
  451
  481
  512
  544
  577
  612
  648
  685
  724
  764
  806
  850
  896
  944
  994
  1,047
  1,102
  1,160
  1,220
  1,283
Total cash flow (excl. dividends), $m
  1,291
  1,307
  1,321
  1,338
  1,358
  1,382
  1,408
  1,437
  1,470
  1,505
  1,223
  1,265
  1,309
  1,357
  1,408
  1,462
  1,520
  1,581
  1,646
  1,715
  1,787
  1,864
  1,946
  2,031
  2,122
  2,217
  2,318
  2,424
  2,535
  2,652
Retained Cash Flow (-), $m
  -132
  -152
  -174
  -195
  -216
  -237
  -258
  -279
  -301
  -323
  -345
  -369
  -393
  -417
  -443
  -469
  -497
  -525
  -555
  -586
  -618
  -652
  -687
  -724
  -763
  -803
  -845
  -889
  -935
  -984
Prev. year cash balance distribution, $m
  51
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  58
  59
  61
  62
  64
  66
  68
  70
  73
  75
  78
  81
  85
  88
  92
  96
  100
  105
  109
  114
  119
  125
  131
  137
  143
  150
  158
  165
  173
  181
Cash available for distribution, $m
  1,210
  1,155
  1,147
  1,143
  1,142
  1,145
  1,150
  1,158
  1,169
  1,182
  878
  896
  917
  940
  965
  993
  1,023
  1,056
  1,091
  1,129
  1,169
  1,212
  1,258
  1,307
  1,359
  1,414
  1,473
  1,534
  1,600
  1,669
Discount rate, %
  7.40
  7.77
  8.16
  8.57
  8.99
  9.44
  9.92
  10.41
  10.93
  11.48
  12.05
  12.66
  13.29
  13.95
  14.65
  15.38
  16.15
  16.96
  17.81
  18.70
  19.63
  20.62
  21.65
  22.73
  23.87
  25.06
  26.31
  27.63
  29.01
  30.46
PV of cash for distribution, $m
  1,127
  994
  907
  823
  742
  666
  593
  524
  459
  399
  251
  214
  181
  151
  124
  101
  80
  63
  48
  37
  27
  20
  14
  10
  6
  4
  3
  2
  1
  1
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

FINANCIAL RATIOS  of  Mallinckrodt (MNK)

Valuation Ratios
P/E Ratio -14.8
Price to Sales 2.7
Price to Book 0.5
Price to Tangible Book
Price to Cash Flow 11.6
Price to Free Cash Flow 17.3
Growth Rates
Sales Growth Rate -75.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -64.5%
Cap. Spend. - 3 Yr. Gr. Rate -12.7%
Financial Strength
Quick Ratio 1
Current Ratio 0.2
LT Debt to Equity 118%
Total Debt to Equity 123.4%
Interest Coverage 0
Management Effectiveness
Return On Assets -1%
Ret/ On Assets - 3 Yr. Avg. 4.2%
Return On Total Capital -1.4%
Ret/ On T. Cap. - 3 Yr. Avg. 2.5%
Return On Equity -3%
Return On Equity - 3 Yr. Avg. 5.2%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 53.7%
Gross Margin - 3 Yr. Avg. 54.8%
EBITDA Margin -11.6%
EBITDA Margin - 3 Yr. Avg. 21.1%
Operating Margin -24.9%
Oper. Margin - 3 Yr. Avg. 1.8%
Pre-Tax Margin -36%
Pre-Tax Margin - 3 Yr. Avg. -8.5%
Net Profit Margin -18.4%
Net Profit Margin - 3 Yr. Avg. 3.9%
Effective Tax Rate 40.8%
Eff/ Tax Rate - 3 Yr. Avg. -63.5%
Payout Ratio 0%

MNK stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MNK stock intrinsic value calculation we used $3222 million for the last fiscal year's total revenue generated by Mallinckrodt. The default revenue input number comes from 2017 income statement of Mallinckrodt. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MNK stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.4%, whose default value for MNK is calculated based on our internal credit rating of Mallinckrodt, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Mallinckrodt.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MNK stock the variable cost ratio is equal to 81.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $-1 million in the base year in the intrinsic value calculation for MNK stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.8% for Mallinckrodt.

Corporate tax rate of 27% is the nominal tax rate for Mallinckrodt. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MNK stock is equal to 1.8%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MNK are equal to 412.2%.

Life of production assets of 10 years is the average useful life of capital assets used in Mallinckrodt operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MNK is equal to 7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $6522 million for Mallinckrodt - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 98 million for Mallinckrodt is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Mallinckrodt at the current share price and the inputted number of shares is $2.1 billion.

RELATED COMPANIES Price Int.Val. Rating
LNTH Lantheus Holdi 13.70 6.80  str.sell
PFE Pfizer 37.33 24.58  sell
NVS Novartis ADR 82.27 59.65  sell
JNJ Johnson&Johnso 125.85 126.96  hold
TEVA Teva Pharmaceu 22.93 22.62  buy

COMPANY NEWS

▶ Mallinckrodt Launches Scientific Advisory Council   [Jun-21-18 04:45PM  PR Newswire]
▶ GoPro Is Among Seven Stocks Poised for a Reversal   [Jun-11-18 01:00PM  TheStreet.com]
▶ Here's Why Mallinckrodt PLC Rose as Much as 16.3% Today   [May-09-18 03:56PM  Motley Fool]
▶ Mallinckrodt: 1Q Earnings Snapshot   [May-08-18 06:22AM  Associated Press]
▶ The '60 Minutes' Effect On Stocks   [07:23AM  Benzinga]
▶ Mallinckrodt plc Announces $300 Million Debt Repayment   [Apr-16-18 04:30PM  PR Newswire]
▶ This News Explains Mallinckrodt's Fall Today   [Feb-28-18 03:42PM  Motley Fool]
▶ US Markets Surge on Tuesday   [12:20PM  GuruFocus.com]
▶ Mallinckrodt beats Street 4Q forecasts   [08:33AM  Associated Press]
▶ [$$] Big Stock Buys: Bluebird, Walgreens, Mallinckrodt   [Feb-20-18 05:00AM  Barrons.com]
▶ Sucampo Pharmaceuticals closes on its $1.2B sale to a U.K. company   [12:14PM  American City Business Journals]
▶ Chuck Royce's Top 5 New Buys of the 4th Quarter   [Feb-13-18 02:49PM  GuruFocus.com]
▶ [$$] New Tax Law Haunts Companies That Did Inversion Deals   [Feb-11-18 11:57PM  The Wall Street Journal]
▶ 5 Opioid Treatment Stocks   [Feb-05-18 06:52AM  Insider Monkey]
▶ Mark Casey Joins Mallinckrodt as General Counsel   [Feb-01-18 09:05AM  PR Newswire]
▶ Mylans Quarterly Revenue Trend   [Jan-10-18 01:35PM  Market Realist]
▶ 6 Stocks Move Higher After XMas   [Dec-27-17 11:17AM  GuruFocus.com]
▶ Company News For Dec 27, 2017   [10:00AM  Zacks]
▶ [$$] Mallinckrodt to Buy Sucampo Pharmaceuticals for About $840 Million   [Dec-26-17 04:31PM  The Wall Street Journal]
▶ Sucampo Pharmaceuticals to be acquired in $1.2B deal   [03:58PM  American City Business Journals]
▶ Mallinckrodt: Maybe This'll Work?   [12:20PM  Barrons.com]
▶ Stocks to Watch: Advanced Micro Devices, Capital One, Apple   [09:38AM  The Wall Street Journal]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.